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Mesenchymal stem cells (MSCs) are promising cells to treat cartilage defects due to their
chondrogenic differentiation potential. However, an inflammatory environment during
differentiation, such as the presence of the cytokine TNFα, inhibits chondrogenesis
and limits the clinical use of MSCs. On the other hand, it has been reported that
exposure to TNFα during in vitro expansion can increase proliferation, migration,
and the osteogenic capacity of MSCs and therefore can be beneficial for tissue
regeneration. This indicates that the role of TNFα on MSCs may be dependent
on the differentiation stage. To improve the chondrogenic capacity of MSCs in the
presence of an inflamed environment, we aimed to determine the effect of TNFα on
the chondrogenic differentiation capacity of MSCs. Here, we report that TNFα exposure
during MSC expansion increased the chondrogenic differentiation capacity regardless
of the presence of TNFα during chondrogenesis and that this effect of TNFα during
expansion was reversed upon TNFα withdrawal. Interestingly, pre-treatment with another
pro-inflammatory cytokine, IL-1β, did not increase the chondrogenic capacity of MSCs
indicating that the pro-chondrogenic effect is specific for TNFα. Finally, we show that
TNFα pre-treatment increased the levels of SOX11 and active β-catenin suggesting
that these intracellular effectors may be useful targets to improve MSC-based cartilage
repair. Overall, these results suggest that TNFα pre-treatment, by modulating SOX11
levels and WNT/β-catenin signaling, could be used as a strategy to improve MSC-based
cartilage repair.
Keywords: mesenchymal stem cells, tumor necrosis factor-alpha, cartilage, regenerative medicine, SOXC
transcription factors, chondrogenesis, tissue engineering
INTRODUCTION
Cartilage has a limited repair capacity and, if left untreated after damage, it will often undergo
progressive, irreversible degeneration. The treatment of cartilage defects still remains challenging
and novel regenerative medicine strategies are needed. Mesenchymal stem cells (MSCs) are
promising cells for cell-based cartilage regeneration approaches (Caplan, 1991; Caplan and Dennis,
2006) because ease of isolation, chondrogenic potential (Johnstone et al., 1998; Pittenger et al., 1999)
and anti-inflammatory properties (Kinnaird et al., 2004; Caplan and Dennis, 2006; Ren et al., 2008;
van Buul et al., 2012). These properties can be affected by factors present in the microenvironment,
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such as pro-inflammatory cytokines. TNFα is one of the pro-
inflammatory cytokines that can be present in symptomatic
cartilage defects (Tsuchida et al., 2014), osteoarthritic cartilage
and synovium (Chu et al., 1991; Kapoor et al., 2011; Tsuchida
et al., 2014), and that contributes to the pathophysiology of
osteoarthritis (reviewed by Fernandes et al., 2002; Goldring and
Otero, 2011).
Exposure to TNFα during MSC chondrogenesis in vitro
reduces the chondrogenic capacity (Wehling et al., 2009),
increasing the expression of aggrecanases and decreasing
expression of proteoglycans (Markway et al., 2016). However
TNFα is known to be involved in several biological processes
such as apoptosis, proliferation and cell survival (Brenner et al.,
2015; Cheng et al., 2019). In addition, there is also evidence
that TNFα can promote tissue regeneration since it can increase
osteogenesis (Daniele et al., 2017) and MSC proliferation and
migration (Bocker et al., 2008; Bai et al., 2017; Shioda et al., 2017).
It has been shown that MSCs primed with TNFα in vitro survive
better than control MSCs when transplanted in vivo (Giannoni
et al., 2010). Overall these data suggest that the effect of TNFα
may depend on the dynamics of exposure and that its effect
may be beneficial forMSC-based tissue regeneration. Specifically,
the effect on chondrogenesis of TNFα administration during
MSC expansion has been incompletely investigated whether in
the presence or absence of an inflamed environment during the
subsequent phase of cell differentiation.
In order to increase the chondrogenic capacity of MSCs
under inflammatory conditions, we hypothesized that TNFα
administration during cell expansion (pre-treatment) would have
a beneficial effect on the subsequent chondrogenesis performed
in the presence of TNFα. Here we demonstrated that TNFα
pre-treatment increases MSC chondrogenesis regardless of the
presence of TNFα during differentiation and that the effect of
TNFα on the chondrogenic capacity is reversible. This pro-
chondrogenic effect could not be obtained by pre-treatment
with interleukin 1β (IL-1β) another pro-inflammatory cytokine
involved in local inflammation in the joint (Goldring and Otero,
2011). Finally, to identify a possible TNFα target pathway in the
pre-treated MSCs, we investigated the levels of the SOXC protein
(SOX4 and SOX11), this group of SRY-related transcription
factors was previously described to be stabilized by TNFα and
involved in cartilage primordia and growth plate formation
(Kato et al., 2015; Bhattaram et al., 2018). In addition, we also
analyzed active β-catenin levels, since SOXC can increase β-
catenin protein levels (Bhattaram et al., 2014) and WNT/β-
catenin signaling can increase the chondrogenic potential of
MSCs (Narcisi et al., 2015).
MATERIALS AND METHODS
MSC Isolation and Expansion
MSCs were isolated from human bone marrow aspirates
from patients (17–73 years old, Table S1) undergoing total
hip replacement after informed consent and with approval
of the ethics committee (MEC 2015-644: Erasmus MC,
Rotterdam). Patients with radiation therapy in the hip area,
hematologic disorders and mental retardation or dementia
were excluded from our study population. MSCs were isolated
by plastic adherence and the day after seeding the non-
adherent cells were washed away with PBS with 1% fetal
calf serum (Gibco, selected batch 41Q2047K). They were
cultured in alpha-MEM (Invitrogen), with 10% fetal calf serum,
1.5µg/ml fungizone (Gibco), 50µg/ml gentamicin (Invitrogen),
1 ng/ml FGF2 (AbD Serotec), and 0.1mM ascorbic acid-2-
phosphate (Sigma-Aldrich). After 10–12 days, the MSCs were
trypsinized and re-seeded at a density of 2,300 cells/cm2.
MSCs in our study were selected based on their capacity to
chondrogenically differentiate, their MSC morphology (small
elongated and spindle-shaped cells) and expansion capacity
(cells with less than 0.15 doublings/day were excluded). To
investigate whether exposure to TNFα during expansion prior
to chondrogenic differentiation (pre-treatment) could inhibit
the negative effect of TNFα, MSCs were pre-treated with
different concentrations of TNFα (0, 1, 10, or 50 ng/ml TNFα,
PeproTech) for different exposure times 24 h, 4–6 days (1
passage) or 8–10 days (2 passages), and then chondrogenically
differentiated in the presence of 0 or 1 ng/ml TNFα. When
indicated, MSCs were first treated with TNFα for 1 passage
(4 days) followed by removal of TNFα for 1 passage (4
days) and subsequently chondrogenically differentiated in the
presence of 1 ng/ml TNFα. To investigate the effect of IL-
1β pre-treatment on the chondrogenic differentiation, MSCs
were pre-treated for 1 passage with different concentrations of
IL-1β (0, 0.1, 1, 10, and 50 ng/ml, PeproTech), followed by
chondrogenic differentiation in the absence of IL-1β. MSCs
from different donors are indicated as donor 1, 2, 4, 5, 6, 7, 8,
or 9.
Chondrogenic Differentiation
To obtain a 3D pellet culture, 2 x 105 MSCs were centrifuged
at 300 g for 8min in polypropylene tubes. To induce
chondrogenesis, the pelleted cells were cultured in DMEM-HG
(Invitrogen), 1% ITS (B&D), 1.5µg/ml fungizone (Invitrogen),
50µg/ml gentamicin (Invitrogen), 1mM sodium pyruvate
(Invitrogen), 40µg/ml proline (Sigma-Aldrich), 10 ng/ml
TGFβ1 (R&D Systems), 0.1mM ascorbic acid 2-phosphate
(Sigma-Aldrich), and 100 nM dexamethasone (Sigma-Aldrich),
referred to as chondrogenic medium (Johnstone et al., 1998).
After 24 h, the medium was renewed with chondrogenic
medium with or without 1 ng/ml TNFα, as indicated. Afterwards
the medium was renewed two times per week for a period
of 4 weeks.
COL2A1 Reporter Assays
Cultures of human bone marrow-derived MSCs from healthy
de-identified adult volunteer donors (31–33 years old, Table S1)
were established as previously described (Lennon and Caplan,
2006) after informed consent. The bone marrow was collected
using a procedure reviewed and approved by the University
Hospitals of Cleveland Institutional Review Board (IRB# 09-90-
195). MSCs from different donors are indicated as donor 3 or
10. Lentiviral constructs for the COL2A1 promoter were placed
upstream of the Gaussia luciferase reporter gene. MSCs were
transduced with the COL2A1 reporter lentivirus as previously
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described for a SOX9 reporter (Correa et al., 2018). MSCs with
the COL2A1 luciferase reporter were expanded as indicated
above. At different time points during chondrogenesis, medium
of MSCs with the COL2A1 reporter was harvested 48 h after the
last medium renewal. Per condition, 50 µl of the medium was
transferred to a white 96-well plate and 20µM coelenterazine
substrate (NanoLight technology) was injected into the
wells. The Gaussia Luciferase (Gluc) activity was measured
using a GloMax-96 Microplate Luminometer (Promega) in
technical duplicates.
CD Marker Analysis
Per condition, 2 x 105 MSCs were re-suspended in 500 µl
FACSFlow solution (BD Biosciences) and stained with antibodies
against human CD45-APC (368515, BioLegend), CD90-APC
(FAB2067A, R&D Systems), CD73-PE (550257, BD Biosciences),
or CD105-FITC (FAB10971F, R&D Systems), following the
manufacturer’s guidelines. Afterwards, the cells were fixed
using 2% formaldehyde (Fluka) and were filtered through 70-
µM filters. Unstained cells were used as a negative control.
Samples were analyzed by flow cytometry using a BD Fortessa
machine (BD Biosciences). The data were analyzed using FlowJo
V10 software.
Apoptosis Analysis
Per condition, 5 x 105 MSCs were re-suspended in 1x Binding
Buffer and stained with Annexin V and Propidium Iodide using
manufacturer’s instructions (all products from eBioscience, San
Diego, USA). Samples were analyzed by flow cytometry using
a BD Fortessa machine (BD Biosciences) and analyzed using
FlowJo V10 software.
(Immuno)Histochemistry
After 4 weeks of chondrogenic induction, pellets were fixed
with 3.8% formaldehyde, embedded in paraffin and sectioned
(6µm). Glycosaminoglycans (GAG) were stained with 0.04%
thionine solution and collagen type-2 was immunostained using
a collagen type-2 primary antibody (II-II 6B3, Developmental
Studies Hybridoma Bank). Antigen retrieval was performed
with 0.1% Pronase (Sigma-Aldrich) in PBS for 30min
at 37◦C, followed by incubation with 1% hyaluronidase
(Sigma-Aldrich) in PBS for 30min at 37◦C to improve
antibody penetration. The slides were pre-incubated with
10% normal goat serum (Sigma-Aldrich) in PBS with 1%
bovine serum albumin (BSA; Sigma-Aldrich). Next, the
slides were incubated for 1 h with collagen type-2 primary
antibody, and then with a biotin-conjugated secondary
antibody (HK-325-UM, Biogenex), alkaline phosphatase-
conjugated streptavidin (HK-321-UK, Biogenex), and the
New Fuchsine chromogen (B467, Chroma Gesellschaft). An




After chondrogenic induction for 28 days, pellets were digested
using 250 µl digestion solution containing in 1 mg/ml Proteinase
K, 1mM iodoacetamide, 10µg/ml Pepstatin A in 50mM Tris,
1mM EDTA buffer (pH 7.6; all Sigma-Aldrich) for 16 h at
56◦C. Next, Proteinase K was inactivated at 100◦C for 10min.
To determine the DNA content, 50 µl cell lysate was treated
with 100 µl heparin solution (8.3 IU/ml) and 50 µl RNase
(0.05 mg/ml) solution for 30min at 37◦C. Next 50 µl ethidium
bromide (25µg/ml) was added and the samples were analyzed
on a Wallac 1420 Victor2 plate reader (Perkin-Elmer) using
an excitation of 340 nm and an emission of 590 nm. In case
the amount of DNA was lower than 1 µg per ml, 50 µl cell
lysate was treated with 50 µl heparin solution and 25 µl RNase
for 30min at 37◦C. After incubation, 30 µl CYQUANT GR
solution (Invitrogen) was added and samples were analyzed
on a SpectraMax Gemini plate reader using an excitation of
480 nm and an emission of 520 nm. DNA sodium salt from
calf thymus was used as a standard (Sigma-Aldrich). GAG
content was determined using the 1,9-dimethylmethylene blue
(DMB) assay, as previously described (Farndale et al., 1986).
In short, 100 µl cell lysate, containing up to 5 µg GAG,
was incubated with 200 µl DMB solution and analyzed using
an extinction of 590 nm and 530 nm. Chondroitin sulfate
sodium salt from shark cartilage was used as a standard
(Sigma-Aldrich).
mRNA Expression Analysis
After chondrogenic induction for 14 or 28 days, pellets were lysed
in RNA-Bee (TEL-TEST) and manually homogenized. RNA was
extracted using chloroform and purified using the RNeasy Kit
(Qiagen), following manufacturer’s guidelines. RNA was reverse-
transcribed with a RevertAid First Strand cDNA synthesis kit
(MBI Fermentas). Real-time polymerase chain reactions were
performed with TaqMan Universal PCR MasterMix (Applied
Biosystems) or SYBR Green MasterMix (Fermentas) using a
CFX96TM PCR detection system (Bio-Rad). Primers are listed in
Table S2 and the genes GAPDH, RPS27A, and HPRT1 were used
as housekeeping genes. The best housekeeping index (BHI) was
calculated using the formula (CtGAPDH∗ CtRPS27a∗ CtHPRT1)1/3.
Relative mRNA levels were calculated using the formula 2−11Ct.
Adipogenic Differentiation
To induce differentiation toward the adipogenic lineage, 2
x 104 cells/cm2 were seeded and cultured in DMEM HG
(Invitrogen) with 10% fetal calf serum (Gibco), 1.5µg/ml
fungizone (Invitrogen), 50µg/ml gentamicin (Invitrogen),
1.0µM dexamethasone (Sigma-Aldrich), 0.2mM indomethacin
(Sigma-Aldrich), 0.01 mg/ml insulin (Sigma-Aldrich) and
0.5mM 3-isobutyl-l-methyl-xanthine (Sigma-Aldrich) for 14
days. In order to visualize intracellular lipid accumulation,
cells were fixed in 3.8% formaldehyde, treated with 0.3% Oil
red O solution (Sigma-Aldrich) for 10min and then washed
with distilled water. In addition, PPARG mRNA expression was
analyzed as indicated above.
Osteogenic Differentiation
To induce differentiation toward the osteogenic lineage, 3 x 103
cells/cm2 were seeded and cultured in DMEM HG (Invitrogen)
with 10% fetal calf serum (Gibco), 1.5µg/ml fungizone
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(Invitrogen), 50µg/ml gentamicin (Invitrogen), 10mM β-
glycerophosphate (Sigma-Aldrich), 0.1µM dexamethasone
(Sigma-Aldrich), and 0.1mM ascorbic acid-2-phosphate
(Sigma-Aldrich) for 14–18 days. For the detection of calcium
deposits (Von Kossa staining), cells were fixed in 3.8%
formaldehyde, hydrated with distilled water, treated with
5% silver nitrate solution (Sigma-Aldrich) for 60min in the
presence of bright light and then washed with distilled water
followed by counterstaining with 0.4% thionine (Sigma-
Aldrich). In addition, ALPL mRNA expression was analyzed as
indicated above.
Western Blot
To test for SMAD2 activation, MSC monolayers were pre-
treated for 4 days with 0 or 50 ng/ml TNFα in standard MSC
growth medium, followed by serum starvation overnight (16 h)
in DMEM-HG (Invitrogen) containing 1% ITS (B&D), 1.5µg/ml
fungizone (Invitrogen), 50µg/ml gentamicin (Invitrogen), 1mM
sodium pyruvate (Invitrogen), 40µg/ml proline (Sigma-Aldrich)
and 0 or 50 ng/ml TNFα. Next, MSCs were stimulated for 30min
with 0 or 10 ng/ml TGFβ1 in the presence or absence of 1 ng/ml
TNFα. To assess the SOXC proteins (SOX11 and SOX4), and
(active) β-catenin levels, MSCs were pre-treated for 4 days with 0
or 50 ng/ml TNFα in standard MSCmedium. Twenty-four hours
prior to harvest, the medium was renewed with standard MSC
growth medium containing 0 or 50 ng/ml TNFα. Western blot
were made using MSC lysates prepared using M-PER lysis buffer
containing 1% Halt Protease Inhibitor and 1% Halt Phosphatase
Inhibitor (Thermo Scientific). Total protein concentration was
determined using a BCA assay (Thermo Scientific). Eight to ten
micrograms of protein was electrophoresed on a 4–12% gradient
SDS-PAGE gel. Proteins were transferred to a nitrocellulose
membrane (Millipore) by semi-wet transfer, followed by blocking
with 5%milk powder dissolved in Tris-buffered saline containing
0.1% Tween (TBST) for 3 h. Membranes were incubated
overnight at 4◦C with primary antibody according to Table S3 in
5% BSA in TBST, followed by incubation at room temperature for
1.5 h with peroxidase-conjugated anti-rabbit secondary antibody
(Cell Signaling, 7074S) in 5% dry milk in TBST. Proteins
were detected using the SuperSignal Wester Pico Complete
Rabbit IgG detection kit (ThermoFisher scientific) following
manufacturer’s instructions.
Statistical Analysis
Data were analyzed using SPSS software (IBM SPSS statistics
25). Normal distribution was tested using the Kolmogorov-
Smirnov test. Since the Kolmogorov-Smirnov test showed that
the COL2A1 reporter data was not normally distributed a Mann-
Whitney U-test was applied to analyze these data. All other
data were normally distributed and a linear mixed model, with
the different conditions considered as fixed parameters and the
donors as random parameters was applied. Bonferroni post-
hoc tests were performed to correct for multiple comparisons.
P-values less than 0.05 were considered statistically significant.
RESULTS
MSCs Pre-treated With TNFα Had an
Increased Chondrogenic Potential When
Subsequently Maintained Under
Stimulation by TNFα During Differentiation
To study if TNFα exposure during MSCs expansion (pre-
treatment) could inhibit the negative effect of TNFα during
chondrogenic differentiation, MSCs were pre-treated with
different concentrations of TNFα and incubation time
prior to chondrogenic differentiation in the presence of
1 ng/ml TNFα (Figure S1A). First, we confirmed that
the presence of 1 ng/ml TNFα during the chondrogenic
phase reduced the ability of MSCs to differentiate
(Figures S1B–D; condition 0/0 vs. 0/1). Pre-treatment
for 1 passage increased GAG deposition in MSC pellets
after chondrogenic induction in the presence of TNFα
(Figure S1C), with the larger effect occurring when the
pre-treatment was performed with 10 and 50 ng/ml TNFα
(Figure S1C; condition 0/1 vs. 10/1 and 50/1). Pre-treatment
with TNFα for 24 h and 2 passages did not have a clear
effect on chondrogenesis (Figures S1B,D; 0/1 vs. 1/1, 10/1
and 50/1). Given these observations, we performed the
rest of the experiments using TNFα pre-treatment for 1
passage (Figure 1A).
Next, we analyzed MSCs from four other donors and
observed that chondrogenic pellets of MSCs pre-treated for
1 passage with 50 ng/ml TNFα had a higher GAG content
after 28 days of chondrogenic induction in the presence
of TNFα compared to MSCs without TNFα pre-treatment
(Figure 1B and Figure S2A; 0/1 vs. 50/1, p = 0.003), while no
effect on DNA content was observed (Figure S2A). Moreover,
GAG staining demonstrated an increased GAG content in
the TNFα pre-treated MSCs at day 28 (Figure 1C; 0/1 vs.
50/1). Staining for collagen type-2 did not show differences
(Figure 1D). No increase in GAG content was observed after
pre-treatment for 1 passage with 10 ng/ml TNFα (Figures 1B,C).
In order to determine whether the effect of 50 ng/ml TNFα
is due to an acceleration of chondrogenic differentiation, first
a non-destructive luciferase-based method was validated as a
proxy for endogenous COL2A1 expression in pellet cultures
(Figure S3) and then applied to assess COL2A1 promoter
activation at day 3 and day 7 of chondrogenic differentiation.
However, no significant differences were observed in COL2A1
promoter activation at day 3 and day 7 (Figure S4A) of
chondrogenesis, suggesting that TNFα pre-treatment did not
increase the rate of chondrogenesis during the first week of
differentiation. Subsequent analysis performed by RT-PCR on
SOX9, COL2A1, and ACAN showed no significant differences
at day 14 and 28 during chondrogenesis between the conditions
(Figures S4A,B).
Overall, these data indicate that pre-treatment of MSC
monolayers with 50 ng/ml TNFα significantly increases the
chondrogenic potential of MSCs when exposed to 1 ng/ml
TNFα during differentiation, but without prompting the
onset of chondrocyte marker expression. For this reason,
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FIGURE 1 | Pre-treatment of MSC monolayers with 50 ng/ml TNFα reduced the inhibitory effect of the cytokine in subsequent chondrogenic conditions. (A)
Schematic overview of the experiment. (B) GAG content of MSC pellets after 28 days of chondrogenic induction. N = 4 donors with 2–5 pellets per donor. (C,D)
Representative images of pellets stained for GAG with (C) thionine and (D) COL2A1 after 28 days of chondrogenic induction. N = 5 donors with 2–3 pellets per donor.
Scale bar represents 250µm.
the following experiments were performed using 50 ng/ml
TNFα pre-treatment.
Pre-treatment With TNFα Increased the
Chondrogenic Potential of MSCs
Regardless the Presence of the Cytokine
During Chondrogenic Differentiation
Next, we tested whether the effect of TNFα pre-treatment on
the chondrogenic potential of MSCs was dependent on the
presence of the cytokine during the differentiation phase. MSCs
were pre-treated during expansion with 0 and 50 ng/ml TNFα,
followed by chondrogenic induction in the absence of TNFα
(Figure 2A). Biochemical assays determined that chondrogenic
pellets of MSCs pre-treated with TNFα had a higher GAG
concentration (p = 0.011; Figure 2B and Figure S2B) and
DNA content (Figure S2B). Histological staining confirmed
increased GAG accumulation (Figure 2C), while no clear effect
on collagen type-2 content was observed after chondrogenic
induction (Figure 2D). To further investigate the effect of
TNFα pre-treatment on the speed of chondrogenic induction
in the absence of TNFα, we determined COL2A1 promoter
activation over time using a COL2A1 luciferase reporter
system. Analysis on 3-day pellet cultures indicated that TNFα
pre-treated MSCs had enhanced luciferase activity, while no
differences between the conditions were observed at day
7 (Figure 2E). These data suggest that TNFα pre-treatment
accelerates chondrogenic differentiation probably via an early
induction of COL2A1 expression among other genes. These data
indicate that TNFα pre-treatment increases the chondrogenic
potential of the MSCs regardless of the presence of TNFα
during chondrogenesis.
To better understand the effect of the TNFα pre-treatment
on MSCs and the specificity for the chondrogenic lineage,
we determined if TNFα increased apoptosis, expansion, and
multilineage differentiation potential. No clear effect on
apoptotic rates was observed after 24 h or 5 days of exposure
to TNFα (Figures S5A,B), but a slight increase in MSC
expansion capacity was detected after pre-treatment for 1
passage (1.4-fold difference; Figure S5C). Adipogenically
induced MSCs pre-treated with TNFα showed less lipid
accumulation compared to control MSCs (p = 0.039;
Figure S5D) and a reduced PPARG expression, which
codes for a transcription factor involved in the adipogenic
differentiation process (Figure S5E). No statistically
significant effect of TNFα pre-treatment on the osteogenic
differentiation capacity was observed although, on average,
mineralization and ALPL expression slightly increased
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FIGURE 2 | Pre-treatment with 50 ng/ml TNFα increased the chondrogenic
potential. (A) Schematic overview of the experiment. (B) GAG content of MSC
pellets after 28 days of chondrogenic induction. N = 3 donors with 2–4 pellets
per donor. (C,D) Representative images of pellets stained for (C) GAG with
thionine and (D) COL2A1 after 28 days of chondrogenic induction. N = 4
donors with 2–3 pellets per donor. Scale bar represents 250µm. (E) Relative
secreted Gaussia Lucificerase (Gluc) activity of medium from MSC pellets
containing the COL2A1 promoter reporter after 3 and 7 days of chondrogenic
induction. Values represent the mean ± SD with 4–6 pellets.
(Figures S5F,G). Overall, these data suggest that TNFα
pre-treatment specifically enhances the chondrogenic potential
of the MSCs.
IL-1β Pre-treatment Did Not Increase the
Chondrogenic Potential of MSCs
We then investigated whether the effect of pre-treatment on
the chondrogenic potential of MSCs was specific for TNFα or
whether IL-1β another pro-inflammatory cytokine can have a
similar effect (Figure 3A). No differences in GAG deposition
were observed after pre-treatment with different concentrations
of IL-1β, based on histology (Figure 3B), indicating that in
contrast to TNFα, IL-1β pre-treatment for 1 passage does
not increase the chondrogenic potential of the MSCs. These
data suggest distinct effects of TNFα and IL-1β pretreatments
on MSCs.
The Effect of TNFα Pre-treatment on the
Chondrogenic Capacity and Expression of
MSC Marker CD105 Was Reversible
To study whether the effect of TNFα is reversible, MSCs were
pre-treated with TNFα for one passage followed by TNFα
withdraw for one additional passage and subsequently subjected
to chondrogenic differentiation (Figure 4A). Interestingly, GAG
staining and biochemical assays showed that the positive effect of
TNFα on the amount of GAG was lost after TNFα withdrawal (p
< 0.001; Figures 4B,C and Figure S2C). No consistent effect on
DNA content and collagen type-2 expression was observed after
chondrogenic induction (Figure 4D and Figure S2C). To further
characterize the MSCs after TNFα pre-treatment, we analyzed
the expression of the MSC markers CD73, CD90, and CD105
(Dominici et al., 2006) together with the negative MSC marker
CD45 (hematopoietic marker). In the control condition without
TNFα pre-treatment, more than 97% of the MSCs expressed
CD73 and CD105, on average 77% of the cells expressed CD90
(Figure 4E), while no cells expressed CD45 (data not shown).
TNFα administration had no effect on the expression of CD73
and CD90, but it significantly decreased the number of CD105
positive MSCs (p = 0.013; Figure 4E), indicating that TNFα
can modulate the MSC phenotype. Interestingly, the number
of CD105 positive cells returned back to control levels after
TNFα withdrawal for one passage (p = 0.020; Figure 4E). These
data indicate that the effect of TNFα pre-treatment on MSC
chondrogenic capacity and phenotype is reversible.
TNFα Pre-treatment Increased SOX11 and
Active β-Catenin Expression in MSCs
To elucidate how TNFα pre-treatment increases the
chondrogenic differentiation capacity of MSCs we first evaluated
effects on the TGFβ1 signaling pathway, since exposure to
TNFα reduced the expression of the TGFβ co-receptor CD105
(Figure 4E). MSCs were then stimulated by 10 ng/ml TGFβ1
for 30min in the presence or absence of 1 ng/ml TNFα.
TGFβ1 increased pSMAD2 levels, however the levels were not
altered by TNFα pre-treatment (0/1 vs. 50/1 and 0/0 vs. 50/0;
Figures S6A,B). These data suggested that TNFα pre-treatment
does not alter the canonical TGFβ1/SMAD2 signaling pathway
in MSCs.
We next studied the effect of TNFα pre-treatment on SOXC
proteins, SOX11 and SOX4 in MSCs. The level of SOX11 protein
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FIGURE 3 | IL-1β pretreatment did not increase the chondrogenic differentiation capacity of MSCs. (A) Schematic overview of experiment. (B) GAG staining with
thionine of MSCs pellets after 28 days culture in chondrogenic medium. Representative image of MSC pretreated for 1 passage with different concentrations IL-1β.
N = 2 donors with 3 pellets per donor. Scale bar represents 250µm.
was significantly increased (6.5-fold; p < 0.001; Figure 5A),
while no significant effect was observed for SOX4 (p = 0.983;
Figure 5A). Finally, since SOXC proteins can stabilize β-catenin
(Bhattaram et al., 2014), we analyzed the level of active β-catenin
in the TNFα pre-treated MSCs. Interestingly, the amount of
active β-catenin was increased after TNFα pre-treatment inMSCs
(2.0-fold; p = 0.003; Figure 5A). This suggests that TNFα pre-
treatment increased canonical WNT signaling in MSCs, possibly
via SOXC stabilization, and thereby enhanced the chondrogenic
potential (Figure 5B).
DISCUSSION
In this study, we demonstrated that TNFα pre-treatment ofMSCs
in monolayers reduced the inhibitory effect of TNFα during
chondrogenic differentiation by boosting the chondrogenic
capacity of these cells. This pro-differentiation effect was both
temporal and specific for the chondrogenic lineage and possibly
mediated by SOX11 and WNT signaling.
SOX11 is a SOXC protein which TNFα is known to stabilize in
fibroblast-like synoviocytes (Bhattaram et al., 2018). SOXC genes
play a crucial role in mesenchymal progenitor cell fate during
skeletal development (reviewed in Lefebvre and Bhattaram,
2016). In addition, SOXC proteins are known to synergize
with canonical WNT signaling via stabilization of β-catenin
(Bhattaram et al., 2014).WNT signaling has been shown before to
play a role in stem cell fate (ten Berge et al., 2008). We previously
showed that induction of WNT signaling during monolayer
increases the expansion and chondrogenic potential of MSCs
(Narcisi et al., 2015, 2016). A link between SOX11 and WNT
signaling has been suggested before in a study with rat MSCs
where Sox11 overexpression also increased the β-catenin level
and resulted in improved cartilage defect repair (Xu et al., 2019).
The results of the current study suggest that SOX11 may play a
role during chondrogenesis of human MSCs. Furthermore, we
show that the expression of SOX11 in MSCs can be modulated
by TNFα.
MSCs are a heterogeneous population of cells with known
intra and inter-donor phenotypic and potency variability. This
is what we also observed in our study where we used MSCs
from both healthy donors and from patients undergoing total
hip replacements. In addition, MSCs from patients with a broad
age range were used for which we cannot exclude a possible
effect of unknown underlying conditions. The differences in the
chondrogenic capacity of MSCs in our study could be due to
differences in cell subpopulations, since the bone marrow houses
MSC subpopulations with different chondrogenic capacities
(Sivasubramaniyan et al., 2018). In addition the age of the donor
can have an effect on the chondrogenic capacity of MSCs (Payne
et al., 2010). Although differences in chondrogenic potential were
observed between MSCs from different patients, a similar effect
after TNFα stimulation was detected in all cases, indicating that
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FIGURE 4 | The effect of TNFα pre-treatment on chondrogenesis and MSC marker expression was reversible after TNFα withdraw. (A) Schematic overview of the
experiment. (B) GAG content of MSC pellets after 28 days of chondrogenic induction. N = 3 donors with 3 pellets per donor. (C,D) Representative images of pellets
stained for (C) GAG with thionine and (D) COL2A1 after 28 days of chondrogenic induction. N = 3 donors with 3 pellets per donors. Scale bar represents 250µm. (E)
Flow cytometry analysis of surface markers CD73, CD90, and CD105. The values represent the percentage of positive cells for the indicated surface marker, N = 3
donors.
TNFα increases the chondrogenic potential of MSCs regardless
of their chondrogenic capacity before TNFα pre-treatment.
Immunophenotyping of MSC is often used to characterize
the cells (Dominici et al., 2006), even though it is a
topic of discussion. We here demonstrated a clear difference
in the expression of CD105, a surface marker commonly
associated with the MSC phenotype (Haynesworth et al., 1992;
Dominici et al., 2006), after pre-treatment with TNFα. In
line with our previous work (Cleary et al., 2016), we further
confirmed that CD105 is not a good marker to predict the
chondrogenic potential of bone marrow-derived MSCs and, on
the contrary, its expression was inversely associated with the
chondrogenic capacity of MSCs. In addition, we show that the
expression of CD105 can be strongly influenced by inflammatory
environmental changes. This could be an explanation for
contradictory published results regarding CD105 and MSCs
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FIGURE 5 | TNFα pre-treatment increased SOXC and active β-catenin expression in MSCs. (A) Western blot for SOXC (SOX11 and SOX4, pan-SOXC antibody) and
non-phospho (active) β-catenin (Ser33/37Thr41). Below: quantification of western blot results relative to GAPDH and normalized to 0 ng/ml TNFα pre-treatment. N =
3 donors with biological duplicates per donor. (B) Possible working mechanism of TNFα pre-treatment on the chondrogenic potential of MSC. Solid lines show known
interactions, [1] Bhattaram et al. Arthritis Rheumatol 2018. [2] Bhattaram et al. J Cell Biol 2014. [3] Narcisi et al. Stem Cell Reports 2015. Dotted lines indicate
unknown interactions.
(Majumdar et al., 2000; Kastrinaki et al., 2008; Jiang et al.,
2010; Asai et al., 2014; Cleary et al., 2016). In addition, a
reduced adipogenic differentiation was observed after TNFα pre-
treatment. It is known that TNFα can reduce the adipogenic
differentiation in 3T3-L1 pre-adipocytes by preventing Pparg
and Cebpa expression (Cawthorn et al., 2007), which is in line
with the reduction of PPARG gene expression levels that we
found after TNFα pre-treatment. In agreement with other studies
(Daniele et al., 2017), we observed that TNFα pre-treatment
slightly increased the osteogenic differentiation capacity ofMSCs.
Overall, these data suggest that TNFα pre-treatment changes the
immunophenotype and multipotency of MSCs.
In this study, we tested three different concentrations and
incubation times and found that pre-treatment with 50 ng/ml
TNFα for 1 passage (4–6 days) increased the chondrogenic
capacity in a more reproducible way than the other conditions.
Since a previous study indicated that 50 ng/ml TNFα can induce
apoptosis in MSC (Cheng et al., 2019), we investigated apoptosis.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 9 June 2020 | Volume 8 | Article 658
Voskamp et al. TNFα Pre-treatment Enhances MSC Chondrogenesis
No large effect on apoptosis was observed after addition of TNFα.
Given the fact that our apoptosis rates are relatively low, we
assume that the pro-chondrogenic effect of TNFα on MSCs in
not due to an increased apoptotic rate. In addition TNFα can
activate several transduction pathways, among which are the NF-
κB, ERK, and JNK pathways (Lu et al., 2016; Bai et al., 2017).
Since a 24-h pre-treatment was not sufficient to observe an effect
on chondrogenesis, we assume that the effect of TNFα on the
chondrogenic capacity of MSCs was not mediated via direct
induction of these pathways, since they are already activated after
24 h (van Buul et al., 2012). In addition, TNFα pre-treatment for
2 passages (8–10) did not increase the chondrogenic potential
suggesting that long-term exposure to TNFα during expansion
does not improve the chondrogenic capacity of MSCs. Moreover,
no increase in chondrogenic differentiation was observed after
pre-treatment with 0.1, 1, 10, and 50 ng/ml IL-1β for 1 passage.
Similar to TNFα, IL-1β is involved in joint inflammation
(Goldring and Otero, 2011). This suggests that TNFα induces
the pro-chondrogenic effect inMSCs via an intracellular pathway
that is not activated by IL-1β. As far as we know, no previous
research has investigated whether IL-1β can increase SOXC and
WNT levels in humanMSCs. Overall, these data indicate that not
all pro-inflammatory cytokines can increase the chondrogenic
potential of MSCs and that the effect seems to be specific
for TNFα.
As previously reported, TNFα exposure during the
chondrogenic differentiation phase reduces chondrogenesis of
MSCs (Markway et al., 2016). Although the TNFα concentrations
used during chondrogenic differentiation in this in vitro study
are higher than the TNFα concentrations in post-traumatic and
OA joints (4–24 pg/ml, Sward et al., 2012; Tsuchida et al., 2014;
Imamura et al., 2015; Alonso et al., 2020), our data indicate that
in vitro pre-treatment with 50 ng/ml TNFα can be beneficial for
cartilage regeneration in an inflamed environment. In addition
we found an association between TNFα pre-treatment and
SOX11 and β-catenin activation in MSCs, therefore regulation
of these pathways might improve cartilage repair in the presence
of TNFα. Overall, the results of our study suggest that exposure
to TNFα during the expansion phase of MSCs could improve
cartilage regeneration approaches.
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